查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
细胞、基因治疗製造服务市场:规模，占有率，趋势分析:各类型，各适应症，各用途，各终端用户，各地区展望，竞争策略，至2030年的各市场区隔预测
市场调查报告书
商品编码
1089963

细胞、基因治疗製造服务市场:规模，占有率，趋势分析:各类型，各适应症，各用途，各终端用户，各地区展望，竞争策略，至2030年的各市场区隔预测

Cell & Gene Therapy Manufacturing Services Market Size, Share & Trends Analysis By Type, By Indication, By Application, By End-user, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 245 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

细胞、基因治疗製造服务的市场规模，预计今后以11.6％的年复合成长率扩大，至2030年达到206亿8,000万美元。製药公司和CDMO的合作，癌症和各种标的疾病的盛行率上升，医药品的研究开发增加，CDMO对尖端技术的高投资，这些要素成为推动市场要素。

本报告提供全球细胞、基因治疗製造服务市场相关调查，市场概要，以及各类型，各适应症，各用途，各终端用户，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 简介

第2章 调查手法

第3章 摘要整理

第4章 市场动态

  • 成长要素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 市场机会
    • 课题
  • COVID-19细胞、基因治疗製造服务市场的影响

第5章 市场变数及预测

  • SWOT分析
  • PESTEL分析
  • 波特的五力分析
  • 热图分析

第6章 全球细胞、基因治疗製造服务市场，各类型，2019年～2030年(100万美元)

  • 细胞治疗
    • 同种异体
    • 自体
    • 病毒载体
  • 基因治疗
    • 非病毒载体
    • 寡核苷酸
    • 病毒载体

第7章 全球细胞、基因治疗製造服务市场，各适应症，2019年～2030年(100万美元)

  • 心血管疾病
  • 中枢神经系统障碍
  • 感染疾病
  • 肿瘤系疾病
  • 眼科疾病
  • 整形外科疾病
  • 其他

第8章 全球细胞、基因治疗製造服务市场，各用途，2019年～2030年(100万美元)

  • 临床製造
  • 商业製造

第9章 全球细胞、基因治疗製造服务市场，各终端用户，2019年～2030年(100万美元)

  • 学术研究
  • 其他
  • 製药公司、生物科技企业

第10章 全球细胞、基因治疗製造服务市场，各地区，2019年～2030年(100万美元)

  • 北美
  • 欧洲
  • 亚太地区
  • 南美
  • 中东、非洲

第11章 企业简介

  • ABL, Inc
  • Andelyn Biosciences
  • Anemocyte Srl
  • BioCentriq
  • Catalent, Inc
  • Cell and Gene Therapy Catapult
  • Charles River Laboratories
  • Commercializing Living Therapies
  • ElevateBio
  • F. Hoffmann-La Roche Ltd.
  • FinVector
  • FUJIFILM Holdings Corporation
  • JRS PHARMA
  • Lonza
  • Merck KGaA
  • NIKON CORPORATION
  • Oxford Biomedica plc
  • Porton Biopharma Limited
  • Resilience
  • RoslinCT
  • Takara Bio Inc
  • The Discovery Labs LLC
  • Thermo Fisher Scientific, Inc
  • Vibalogics
  • WuXi AppTec
简介目录
Product Code: BIOT2229

Global Cell & Gene Therapy Manufacturing Services Market projected to be worth USD 20.68 billion by 2030.

According to SPER Market Research, the Cell & Gene Therapy Manufacturing Services Market estimated to reach USD 20.68 billion by 2030 with a CAGR of 11.6%. The collaboration between pharmaceutical companies and CDMOs, rising prevalence of cancer and various targeted disease, rising pharmaceutical research & development, High investments by CDMOs in advanced technology; these factors act as the fuel to the escalation of the market.

Impact of COVID-19 on the Cell & Gene Therapy Manufacturing Services Market

Because of the outbreak of COVID-19, there is disruption of clinical trials due to the deferral of patient enrolment. Clinical trials such as; cardiovascular disease, respiratory disease, oncology, anti-infective, were the worst-hit in this time. This leads to the squeeze of production and research.

Scope of the report:

  • Market size available for years: 2019-2030
  • Base year considered: 2021
  • Forecast period: 2022-2030
  • Segments covered: By Product, By Region
  • Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • Companies Covered: ABL Inc., Andelyn Biosciences, Anemocyte Srl, BioCentriq, Catalent, Inc., Cell and Gene Therapy Catapult, Charles River Laboratories, Commercializing Living Therapies, ElevateBio, F. Hoffmann-La Roche Ltd., FinVector, FUJIFILM Holdings Corporation, JRS PHARMA, Lonza, Merck KGaA, NIKON CORPORATION, Oxford Biomedica plc, Porton Biopharma Limited, Resilience, RoslinCT, Takara Bio Inc., The Discovery Labs LLC, Thermo Fisher Scientific, Inc., Vibalogics, WuXi AppTec

Driver: rising investments in pharmaceutical Research & Development

The key drivers to the escalation of the market are; towering prevalence of cancer and other target diseases, rising investments in pharmaceutical research & development, funding in advanced technologies by CDMOs, escalating partnerships and agreements among CDMOs and pharmaceutical companies.

Restraint: High running costs coupled with cell & gene therapy manufacturing

The manufacturing of cell & gene therapy is costly; this might resist the expansion of market.

Opportunity: growing figure of cell & gene therapy clinical trials

The demand for cell & gene therapies is escalating globally, the elevated number of cell & gene therapy clinical trials; give the impetus to the top player in this market.

Challenges:

There is chances of superfluous outcomes and threat of mutagenesis; are the challenges to this market.

Global Cell & Gene Therapy Manufacturing Services Market, By Type:

Based on the Type, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Cell Therapy {Allogeneic (Hematopoietic Stem Cells, Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Natural Killer Cells, Other Allogeneic Cells, T-cells), Autologous (Hematopoietic Stem Cells, Mesenchymal Stem Cells, Natural Killer Cells, T-cells), Viral Vector (Adeno-associated Virus Vectors, Other Viral Vectors, Retroviral Vectors)}, Gene Therapy {Non-viral Vector, Oligonucleotides, Viral Vector (Retroviral Vectors, Adeno-associated Virus Vectors, Other Viral Vectors)}.

Global Cell & Gene Therapy Manufacturing Services Market, By Indication:

Based on the Indication, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Cardiovascular Diseases, Central Nervous System Disorders, Infectious Diseases, Oncology Diseases, Ophthalmology Diseases, Orthopaedic Diseases, Other Indications

Global Cell & Gene Therapy Manufacturing Services Market, By Application:

Based on the Application, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Clinical Manufacturing, Commercial Manufacturing.

Global Cell & Gene Therapy Manufacturing Services Market, By End User:

Based on the End-Users, Global Cell & Gene Therapy Manufacturing Services Market is segment as; Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Other End Users.

Global Cell & Gene Therapy Manufacturing Services Market, By Region:

North America owns the prime share of this market; this is due to the increasing prevalence of cancer, increasing research in stem cell and cancer in this region.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Cell & Gene Therapy Manufacturing Services Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Cell & Gene Therapy Manufacturing Services Market, By Type, 2019-2030 (USD Million)

  • 6.1. Cell Therapy
    • 6.1.1. Allogeneic
      • 6.1.1.1. Hematopoietic Stem Cells
      • 6.1.1.2. Induced Pluripotent Stem Cells
      • 6.1.1.3. Mesenchymal Stem Cells
      • 6.1.1.4. Natural Killer Cells
      • 6.1.1.5. Other Allogeneic Cells
      • 6.1.1.6. T-cells
    • 6.1.2. Autologous
      • 6.1.2.1. Hematopoietic Stem Cells
      • 6.1.2.2. Mesenchymal Stem Cells
      • 6.1.2.3. Natural Killer Cells
      • 6.1.2.4. T-cells
    • 6.1.3. Viral Vector
      • 6.1.3.1. Adeno-associated Virus Vectors
      • 6.1.3.2. Other Viral Vectors
      • 6.1.3.3. Retroviral Vectors
  • 6.2. Gene Therapy
    • 6.2.1. Non-viral Vector
    • 6.2.2. Oligonucleotides
      • 6.2.2.1. Other Non-viral Vectors
    • 6.2.3. Viral Vector
      • 6.2.3.1. Retroviral Vectors
      • 6.2.3.2. Adeno-associated Virus Vectors
      • 6.2.3.3. Other Viral Vectors

7. Global Cell & Gene Therapy Manufacturing Services Market, By Indication, 2019-2030 (USD Million)

  • 7.1. Cardiovascular Diseases
  • 7.2. Central Nervous System Disorders
  • 7.3. Infectious Diseases
  • 7.4. Oncology Diseases
  • 7.5. Ophthalmology Diseases
  • 7.6. Orthopedic Diseases
  • 7.7. Other Indications

8. Global Cell & Gene Therapy Manufacturing Services Market, By Application, 2019-2030 (USD Million)

  • 8.1. Clinical Manufacturing
  • 8.2. Commercial Manufacturing

9. Global Cell & Gene Therapy Manufacturing Services Market, By End User, 2019-2030 (USD Million)

  • 9.1. Academic & Research Institutes
  • 9.2. Other End Users
  • 9.3. Pharmaceutical & Biotechnology Companies

10. Global Cell & Gene Therapy Manufacturing Services Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. ABL, Inc.
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Andelyn Biosciences
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Anemocyte Srl
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. BioCentriq
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Catalent, Inc.
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Cell and Gene Therapy Catapult
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Charles River Laboratories
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Commercializing Living Therapies
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. ElevateBio
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. F. Hoffmann-La Roche Ltd.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. FinVector
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. FUJIFILM Holdings Corporation
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. JRS PHARMA
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Lonza
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. Merck KGaA
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. NIKON CORPORATION
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. Oxford Biomedica plc
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Porton Biopharma Limited
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. Resilience
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. RoslinCT
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments
  • 11.21. Takara Bio Inc.
    • 11.21.1. Company details
    • 11.21.2. Financial outlook
    • 11.21.3. Product summary
    • 11.21.4. Recent developments
  • 11.22. The Discovery Labs LLC
    • 11.22.1. Company details
    • 11.22.2. Financial outlook
    • 11.22.3. Product summary
    • 11.22.4. Recent developments
  • 11.23. Thermo Fisher Scientific, Inc.
    • 11.23.1. Company details
    • 11.23.2. Financial outlook
    • 11.23.3. Product summary
    • 11.23.4. Recent developments
  • 11.24. Vibalogics
    • 11.24.1. Company details
    • 11.24.2. Financial outlook
    • 11.24.3. Product summary
    • 11.24.4. Recent developments
  • 11.25. WuXi AppTec
    • 11.25.1 Company details
    • 11.25.2 Financial outlook
    • 11.25.3 Product summary
    • 11.25.4 Recent developments

10. Global Cell & Gene Therapy Manufacturing Services Market, By Region, 2019-2030 (USD Million)

  • 10.1. North America
    • 10.1.1. United States
    • 10.1.2. Canada
    • 10.1.3. Mexico
  • 10.2. Europe
    • 10.2.1. Germany
    • 10.2.2. United Kingdom
    • 10.2.3. France
    • 10.2.4. Italy
    • 10.2.5. Spain
    • 10.2.6. Rest of Europe
  • 10.3. Asia-Pacific
    • 10.3.1. China
    • 10.3.2. Japan
    • 10.3.3. India
    • 10.3.4. Australia
    • 10.3.5. South Korea
    • 10.3.6. Rest of Asia-Pacific
  • 10.4. South America
    • 10.4.1. Brazil
    • 10.4.2. Argentina
    • 10.4.3. Rest of South America
  • 10.5. Middle East & Africa
    • 10.5.1. Kingdom of Saudi Arabia
    • 10.5.2. United Arab Emirates
    • 10.5.3. Rest of Middle East & Africa

11. Company Profiles

  • 11.1. ABL, Inc.
    • 11.1.1. Company details
    • 11.1.2. Financial outlook
    • 11.1.3. Product summary
    • 11.1.4. Recent developments
  • 11.2. Andelyn Biosciences
    • 11.2.1. Company details
    • 11.2.2. Financial outlook
    • 11.2.3. Product summary
    • 11.2.4. Recent developments
  • 11.3. Anemocyte Srl
    • 11.3.1. Company details
    • 11.3.2. Financial outlook
    • 11.3.3. Product summary
    • 11.3.4. Recent developments
  • 11.4. BioCentriq
    • 11.4.1. Company details
    • 11.4.2. Financial outlook
    • 11.4.3. Product summary
    • 11.4.4. Recent developments
  • 11.5. Catalent, Inc.
    • 11.5.1. Company details
    • 11.5.2. Financial outlook
    • 11.5.3. Product summary
    • 11.5.4. Recent developments
  • 11.6. Cell and Gene Therapy Catapult
    • 11.6.1. Company details
    • 11.6.2. Financial outlook
    • 11.6.3. Product summary
    • 11.6.4. Recent developments
  • 11.7. Charles River Laboratories
    • 11.7.1. Company details
    • 11.7.2. Financial outlook
    • 11.7.3. Product summary
    • 11.7.4. Recent developments
  • 11.8. Commercializing Living Therapies
    • 11.8.1. Company details
    • 11.8.2. Financial outlook
    • 11.8.3. Product summary
    • 11.8.4. Recent developments
  • 11.9. ElevateBio
    • 11.9.1. Company details
    • 11.9.2. Financial outlook
    • 11.9.3. Product summary
    • 11.9.4. Recent developments
  • 11.10. F. Hoffmann-La Roche Ltd.
    • 11.10.1. Company details
    • 11.10.2. Financial outlook
    • 11.10.3. Product summary
    • 11.10.4. Recent developments
  • 11.11. FinVector
    • 11.11.1. Company details
    • 11.11.2. Financial outlook
    • 11.11.3. Product summary
    • 11.11.4. Recent developments
  • 11.12. FUJIFILM Holdings Corporation
    • 11.12.1. Company details
    • 11.12.2. Financial outlook
    • 11.12.3. Product summary
    • 11.12.4. Recent developments
  • 11.13. JRS PHARMA
    • 11.13.1. Company details
    • 11.13.2. Financial outlook
    • 11.13.3. Product summary
    • 11.13.4. Recent developments
  • 11.14. Lonza
    • 11.14.1. Company details
    • 11.14.2. Financial outlook
    • 11.14.3. Product summary
    • 11.14.4. Recent developments
  • 11.15. Merck KGaA
    • 11.15.1. Company details
    • 11.15.2. Financial outlook
    • 11.15.3. Product summary
    • 11.15.4. Recent developments
  • 11.16. NIKON CORPORATION
    • 11.16.1. Company details
    • 11.16.2. Financial outlook
    • 11.16.3. Product summary
    • 11.16.4. Recent developments
  • 11.17. Oxford Biomedica plc
    • 11.17.1 Company details
    • 11.17.2 Financial outlook
    • 11.17.3 Product summary
    • 11.17.4 Recent developments
  • 11.18. Porton Biopharma Limited
    • 11.18.1. Company details
    • 11.18.2. Financial outlook
    • 11.18.3. Product summary
    • 11.18.4. Recent developments
  • 11.19. Resilience
    • 11.19.1. Company details
    • 11.19.2. Financial outlook
    • 11.19.3. Product summary
    • 11.19.4. Recent developments
  • 11.20. RoslinCT
    • 11.20.1. Company details
    • 11.20.2. Financial outlook
    • 11.20.3. Product summary
    • 11.20.4. Recent developments
  • 11.21. Takara Bio Inc.
    • 11.21.1. Company details
    • 11.21.2. Financial outlook
    • 11.21.3. Product summary
    • 11.21.4. Recent developments
  • 11.22. The Discovery Labs LLC
    • 11.22.1. Company details
    • 11.22.2. Financial outlook
    • 11.22.3. Product summary
    • 11.22.4. Recent developments
  • 11.23. Thermo Fisher Scientific, Inc.
    • 11.23.1. Company details
    • 11.23.2. Financial outlook
    • 11.23.3. Product summary
    • 11.23.4. Recent developments
  • 11.24. Vibalogics
    • 11.24.1. Company details
    • 11.24.2. Financial outlook
    • 11.24.3. Product summary
    • 11.24.4. Recent developments
  • 11.25. WuXi AppTec
    • 11.25.1 Company details
    • 11.25.2 Financial outlook
    • 11.25.3 Product summary
    • 11.25.4 Recent developments